Latest Breaking News On - மணி ஆரோக்கியம் இன்க் - Page 1 : comparemela.com

Sarcoidosis Drug Market 2021 – Research Scope, Regional Insights, Company Profile and Recent Develop

Sarcoidosis Drug Market 2021 – Research Scope, Regional Insights, Company Profile and Recent Develop
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongUnited kingdomNew zealandSouth koreaSouth africaUnited arab emiratesSaudi arabiaAsia pacificFresenius umwelttechnik gmbCustom researchResearch reportAdvenchen laboratoriesTeam market researchBellus health incMerck co inc

Morganti & Co , P L C Announces the Filing of a Securities Class Action on Behalf of Investors Who Acquired Bellus Health, Inc

Press release content from Business Wire. The AP news staff was not involved in its creation. Morganti & Co., P.L.C. Announces the Filing of a Securities Class Action on Behalf of Investors Who Acquired Bellus Health, Inc. May 15, 2021 GMT TORONTO (BUSINESS WIRE) May 15, 2021 Morganti & Co., A pro-investor law firm with licensed and experienced lawyers in Canada and the United States that represent investors announces the filing of a securities class action on behalf of investors who purchased or otherwise acquired common stock of Bellus Health, Inc. (“Bellus” or “Company”) (NASDAQ: BLU, TSX: BLU, FWB: BHN0) from September 5, 2019 through July 5, 2020, inclusive (the “Class Period”).

New yorkUnited statesManjit singhKim spencer mcpheeBellus or companyMorganti coNasdaq or toronto stock exchangeBellus health incBellus healthToronto stock exchangeKim spencer mcphee barristersAndrew morgantiBusiness wireபுதியது யார்க்ஒன்றுபட்டது மாநிலங்களில்மன்ஜித் சிங்

DEADLINE ALERT: Bragar Eagel & Squire, P C Reminds Investors That a Class Action Lawsuit Has Been Filed Against Bellus Health, Inc and Encourages Investors to Contact the Firm

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Bellus Health, Inc. and Encourages Investors to Contact the Firm Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors that purchased Bellus Health, Inc. securities between September 5, 2019 and July 5, 2020, inclusive . Investors have until May 17, 2021 to apply to the Court to be appointed as … Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors that purchased Bellus Health, Inc. (NASDAQ: BLU) securities between September 5, 2019 and July 5, 2020, inclusive (the “Class Period”). Investors have u

New yorkUnited statesSouth carolinaBrandon walkerBragar eagel squireMelissa fortunatoMarion passmoreUnited states district courtBellus health incBragar eagelSouthern districtBellus healthClass periodபுதியது யார்க்ஒன்றுபட்டது மாநிலங்களில்தெற்கு கரோலினா

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BELLUS Health Inc - BLU

NEW YORK, May 13, 2021 /PRNewswire/ Â Pomerantz LLP is investigating claims on behalf of investors of Â BELLUS Health Inc.Â ( BELLUS or the Company )Â (NASDAQ:Â BLU).Â Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.comÂ or 888-476-6529, ext. 7980. The investigation concerns whether BELLUS Lidar and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.Â - Advertisement - On July 6, 2020, Bellus provided investors with an update regarding its product BLU-5937 , in development as a treatment for chronic cough.Â Bellus announced that the drug had failed a Phase 2 study of chronic cough patients for whom other treatments had not worked. Â Specifically, BLU-5937 was not significantly better than a placebo at reducing the frequency at which patients coughed.Â

New yorkUnited statesFrance generalLos angelesAbrahaml pomerantzRoberts willoughbyPomerantz firmBellus health incNasdaq nms bluNew yorkNorth eastUnited states of americaNorth americaபுதியது யார்க்ஒன்றுபட்டது மாநிலங்களில்பிரான்ஸ் ஜநரல்

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BELLUS Health Inc

Share this article Share this article NEW YORK, May 13, 2021 /PRNewswire/ Pomerantz LLP is investigating claims on behalf of investors of BELLUS Health Inc. ( BELLUS or the Company ) (NASDAQ: BLU). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether BELLUS Lidar and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On July 6, 2020, Bellus provided investors with an update regarding its product BLU-5937 , in development as a treatment for chronic cough. Bellus announced that the drug had failed a Phase 2 study of chronic cough patients for whom other treatments had not worked. Specifically, BLU-5937 was not significantly better than a placebo at reducing the frequency at which patients coughed.

New yorkUnited statesFrance generalLos angelesAbrahaml pomerantzRoberts willoughbyPomerantz firmBellus health incPomerantz llpபுதியது யார்க்ஒன்றுபட்டது மாநிலங்களில்பிரான்ஸ் ஜநரல்லாஸ் ஏஞ்சல்ஸ்ராபர்ட்ஸ் விருப்பம்போமேரதண்தஜ் நிறுவனம்மணி ஆரோக்கியம் இன்க்